AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06061107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook for Geriatric Prearranged Medical Care Consultation
Description: The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention.
Study NCT06505525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-articular reconstruction with the Anterolateral Ligament
Description: Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
Study NCT06505525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-articular reconstruction with the Anterolateral Ligament
Description: Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
Study NCT06389994 — intervention group
Intervention type: DEVICE
Intervention: Esophageal String Test
Description: The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel mycobacterial culture techniques
Description: We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
Study NCT04529954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid delivered to ICV
Description: Valproic Acid delivered to ICV via an implantable pump and catheter system
Study NCT05579002 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and tests
Description: Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1) the Action Research Arm Test (ARAT) 2) modified 400-point assessment.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel sputum smear microscopy techniques
Description: We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sputum-based molecular assays
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tongue swab-based molecular assays
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine LAM assays
Description: We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood-based host immune response assays
Description: We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath-based assays
Description: We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
Study NCT04675294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: IV Q3W
Study NCT04675294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV Q3W
Study NCT04675294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: IV Q3W
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based digital health tools
Description: We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
Study NCT06021015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
Description: Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
Study NCT06021015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan and HepaSphere Microspheres
Description: Irinotecan and HepaSphere Microspheres
Study NCT05584644 — intervention group
Intervention type: DRUG
Intervention: Palbociclib plus hormonal treatment - first line treatment
Description: Palbociclib plus hormonal treatment
Study NCT05584644 — intervention group
Intervention type: DRUG
Intervention: Palbociclib plus hormonal treatment - second line treatment
Description: Palbociclib plus hormonal treatment
Study NCT05322642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPA
Description: UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phage-based assays
Description: We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cartridge-based molecular assays for detecting drug resistance
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Study NCT05322642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition (Progressive Relaxation Training)
Description: Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
Study NCT06053736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIVE Contact Lens
Description: REVIVE Contact Lens
Study NCT04796298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ballistic Hamstring Stretching
Description: Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
Study NCT04796298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hamstring Extender Exercise
Description: Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
Study NCT04796298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
Study NCT05547841 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography acquisition
Description: Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
Study NCT04923958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sequencing-based assays for detecting drug resistance
Description: We will evaluate targeted and whole genome sequencing assays.
Study NCT06172829 — intervention group
Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.
Study NCT05151549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/3weeks
Study NCT05151549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Study NCT05985616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Training
Description: High intensity resistance training will be performed 3 times a day for sixteen weeks
Study NCT05568966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venepuncture to draw up to 24mL of venous blood.
Study NCT05568966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Capillary blood draw
Study NCT06188403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic surgery (lefort1)
Description: Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
Study NCT05960656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Study NCT04946123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine+Selenium
Description: Supplementation with L-carnitine and Selenium
Study NCT05394987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by >+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., >50% of waking hours) for the duration of the study.
Study NCT04847557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04847557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05729386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 1)
Description: Linagliptin and Metformin Hydrochloride Tablet
Study NCT05729386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study NCT05729386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 2)
Description: Linagliptin and Metformin Hydrochloride Tablet
Study NCT05729386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study NCT06032247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise program- UL
Description: Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression.
Study NCT06032247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise program- BL
Description: Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression.
Study NCT04949113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab + nivolumab
Description: 2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
Study NCT06337578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - ALS
Description: ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview.
Study NCT06337578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
Description: AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory.
Study NCT05960656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablet
Study NCT05960656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg
Description: A medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
Study NCT05960656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg + Empagliflozin (25 mg)
Description: Combination of two medications used in the management and treatment of type 2 diabetes mellitus in the thiazolidinedione and sodium-glucose co-transporter (SGLT-2) class of medications, respectively.
Study NCT05489276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2825 injection
Description: TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
Study NCT06337578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone-based and in-person cognitive screening - NIs
Description: NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person.
Study NCT04949113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant nivolumab
Description: Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
Study NCT06031545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long peripheral venous catheters for use
Description: Long peripheral venous catheters for use during the perioperative period in obese patients
Study NCT06031545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Midline catheter
Description: Midline catheters for use during the perioperative period in obese patients
Study NCT04657302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
Study NCT04657302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
Study NCT04988997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 50mg/PBO
Description: Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
Study NCT04657302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Study NCT05060003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is provided by Genentech.
Study NCT05060003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is provided by Genentech.
Study NCT05060003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is provided by Genentech.
Study NCT05060003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera Assay
Description: * To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)
Study NCT04988997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 100mg/PBO
Description: Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
Study NCT04988997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 50/50 mg
Description: Vurolenatide - 50 mg weekly SC administration
Study NCT04988997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO - weekly SC administration
Study NCT05060003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signatera Assay
Description: * To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)
Study NCT05408403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia TFPB
Description: Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
Study NCT05408403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia QLB
Description: Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
Study NCT04810429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumoxin A
Description: XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose.
Study NCT04810429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ surgical arthroscopy
Description: TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.